BioCentury | Jun 11, 2020

Cullinan adds first-in-class asset in hot NK cell checkpoint space

The latest addition to Cullinan’s oncology portfolio is a mAb against MICA that’s set to become the first compound in the clinic against the NK cell target. Through a deal announced on Thursday, Cullinan Oncology...
BioCentury | Sep 13, 2019

After single exit, Avalon seeks path forward for build-to-buy assets from GSK deal

With GSK effectively bowing out of a 2013 build-to-buy deal with Avalon Ventures after delivering just one exit, the VC is seeking to navigate a future for a handful of Phase I-ready programs it created...
BC Innovations | Aug 17, 2017

Built to purpose

With almost 40 start-ups engaging in build-to-buy deals since 2013 and an average 2-4 years for up or down decisions, the next year could see a spate of acquisitions -- or options declined -- that...
BC Innovations | Mar 23, 2017
Tools & Techniques

The phenomics phenomenon

Having been upstaged by the dawning of genomics over 20 years ago, phenotypic screening is making a comeback as improvements in disease models, advances in microscopy and the rise of machine learning are making it...
BC Innovations | Nov 17, 2016
Product R&D

Hemorrhaging targets

An analysis of the almost 5,000 abstracts set to be presented at the 2016 American Society of Hematology (ASH) meeting next month indicates this year’s hot topics in preclinical research include a spattering of new...
BC Extra | Sep 16, 2016
Company News

Management tracks

EMA said Head of International Affairs Emer Cooke will leave the agency to join the World Health Organization as head of regulation of medicines and other health technologies in WHO's essential medicines and health products...
BC Week In Review | May 30, 2016
Company News

PDI Therapeutics Inc., GlaxoSmithKline cancer news

Avalon Ventures launched cancer immunotherapy company PDI Therapeutics as part of an expanded build-to-buy partnership with GlaxoSmithKline. PDI Therapeutics is developing antibodies that inhibit protein disulfide isomerases (PDIs) to treat cancer. Overexpression of PDI can...
BC Extra | May 21, 2016
Company News

Avalon launches cancer play PDI Therapeutics

Avalon Ventures launched cancer immunotherapy play PDI Therapeutics Inc. (La Jolla, Calif.) as part of an expanded build-to-buy partnership with GlaxoSmithKline plc (LSE:GSK; NYSE:GSK). The newco is the first Avalon has launched since the partners...
BC Week In Review | Jan 25, 2016
Company News

J&J, University of Dundee, University of Edinburgh, University of Oxford deal

Johnson & Johnson’s Janssen Pharmaceutica N.V. unit partnered with the universities’ National Phenotypic Screening Centre (NPSC) under the group’s Phenomics Discovery Initiative (PDi) to develop assays to screen Janssen compounds. Janssen will nominate eight phenotypic...
BC Week In Review | Jan 25, 2016
Company News

University of Dundee, University of Edinburgh, University of Oxford deal

The universities launched the National Phenotypic Screening Centre (NPSC) and the Phenotypic Discovery Initiative (PDi) to develop phenotypic assays for drug discovery. Through the PDi, industry partners will develop phenotypic assays to identify targets and...
Items per page:
1 - 10 of 36